INS and type 2 diabetes mellitus: The BEYOND trial [7] evaluated the feasibility of switching individuals with type 2 diabetes and inadequate glycemic control from a basal-bolus insulin regimen to a fixed-ratio combination (FRC) of basal insulin with a GLP-1 RA or a sodium-glucose co-transporter 2 inhibitor (gliflo-combo).